Table 1

Baseline characteristics of patients

Feature

MCTDa

Controls

P value, MCTD vs. controls

MCTDb CVD+

MCTD CVD-

P value, MCTD/CVD+ vs. MCTD/CVD-


n

50

38

23

27

Age at investigation (years)

50.2 ± 10.0

50.4 ± 10.3

0.936

50.1 ± 10.7

50.2 ± 9.5

0.99

Disease duration (years)

9.56 ± 6.8 (3 to 26)

-

-

10.3 ± 6.6 (3 to 26)

8.9 ± 6.9 (3 to 25)

0.481

SBP (mmHg)

137.4 ± 21.1

132.9 ± 19.6

0.367

144.7 ± 19.5

131.1 ± 20.6

0.037

DBP (mmHg)

90.9 ± 15.9

86.6 ± 15.3

0.215

88.5 ± 14.9

92.9 ± 16.8

0.299

BMI (kg/m2)

24.2 ± 1.3

23.2 ± 1.1

0.77

23.9 ± 1.1

24.81.9

0.383

Smoking

Former smokers

5 (10%)

5 (13.1)

0.7401

2 (8.6)

3 (11.1)

1.0

Nonsmokers

45 (90%)

33 (86.8%)

0.7401

21 (91.3)

24 (88.8)

1.0

Serum triglyceride (mmol/l)

1.611 ± 0.76

1.6 ± 0.79

0.755

1.5 ± 0.82

1.72 ± 0.70

0.3367

Total cholesterol (mmol/l)

5.94 ± 1.18

5.47 ± 1.03

0.047

5.8 ± 1.2

6.06 ± 1.13

0.108

HDL-C (mmol/l)

1.69 ± 0.5

1.68 ± 0.49

0.943

1.56 ± 0.48

1.8 ± 0.5

0.22

LDL-C (mmol/l)

3.62 ± 1.15

3.23 ± 0.88

0.148

3.52 ± 1.19

3.7 ± 1.12

0.333

ApoA1 (g/l)

1.31 ± 0.36

1.72 ± 0.47

<0.001

1.27 ± 0.3

1.33 ± 0.4

0.003

ApoB (g/l)

0.95 ± 0.31

0.91 ± 0.13

0.693

0.98 ± 0.38

0.89 ± 0.15

0.92

Paraoxonase-1 activity

113.6 ± 70.6

187.4 ± 68.3

<0.001

84.32 ± 69.66

138.7 ± 62.3

<0.001

hs-CRP (mg/l)

15.2 ± 9.62

1.44 ± 0.99

<0.001

22.1 ± 9.78

9.36 ± 3.96

<0.001

ESR (mm/hour)

20.2 ± 17.8

8.3 ± 3.9

<0.001

26.5 ± 17.6

14.4 ± 16.2

0.014


ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; ESR: erythrocyte sedimentation rate; HDL-C, high-density lipoprotein-cholesterol; hs-CRP: high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; MCTD, mixed connective tissue disease; SBP, systolic blood pressure. aMann-Whitney U test. bKruskal-Wallis analysis of variance.

Soltesz et al. Arthritis Research & Therapy 2010 12:R78   doi:10.1186/ar2999

Open Data